{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:53:10Z","timestamp":1773071590148,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K23GM147350"],"award-info":[{"award-number":["K23GM147350"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K23GM147350"],"award-info":[{"award-number":["K23GM147350"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013607","name":"American College of Clinical Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Transgender people have unmet health needs related to chronic conditions such as dementia, osteoporosis and hypertension. Community\u2010driven advocacy increased transgender representation in phase III trials for pharmacological prevention of HIV, but the extent to which drug trials for other conditions have included transgender people is unknown. We investigated the extent to which trials of drugs and biologics represented transgender people across therapeutic areas on <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cross\u2010sectional analysis of trials of drugs and biologics registered on <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> from 2007\u20132023. We included efficacy and effectiveness trials (phase II\u2013IV) with transgender\u2010related terms (e.g. \u2018transgend*\u2019). We labelled trials as <jats:italic>Inclusive<\/jats:italic> or <jats:italic>Exclusive<\/jats:italic> of transgender people using the trial eligibility criteria. We compared trials (therapeutic area, trial design, enrolment), summarized trials registered from 2008 onward and characterized participant enrolment for Inclusive trials with primary trial publications. We summarized continuous data using median (range), categorical data using frequencies and percentages and compared trial characteristics using Fisher's exact test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010seven trials represented transgender people. Characteristics were similar between 85 Inclusive and 12 Exclusive trials. Among Inclusive trials, 58% focused on infectious diseases (e.g. treatment or prevention of HIV and COVID\u201019), 15% on mental health (e.g. post\u2010traumatic stress disorder, substance use\u2010related disorders), and the remainder focused on endocrine (9%), pain (5%), digestive system disorders (1%) and neoplasms (1%). Twenty (of 25) trials reported enrolment of transgender participants in primary trial publications or reported results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Transgender\u2010inclusive trials have increased since 2008. Most trials focused on infectious diseases and mental health. Investigators should increase opportunities to include of transgender people in trials of drugs and biologics for chronic diseases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16076","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T03:04:13Z","timestamp":1715051053000},"page":"2332-2342","source":"Crossref","is-referenced-by-count":8,"title":["Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-3588","authenticated-orcid":false,"given":"Zachary","family":"Schonrock","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sierra","family":"Brackeen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikka E.","family":"Delarose","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany Q.\u2010D.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-1060","authenticated-orcid":false,"given":"Lauren R.","family":"Cirrincione","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)00683\u20108"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010publhealth\u2010052620\u2010100313"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1728212"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301241"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304727"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2016.0208"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13052"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115339"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2020.101259"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267780"},{"key":"e_1_2_11_12_1","unstructured":"US Food & Drug Administration.FDA action plan to enhance the collection and availability of demographic subgroup data. 2014. Accessed December 3 2023.\u00a0https:\/\/www.fda.gov\/media\/89307\/download"},{"key":"e_1_2_11_13_1","unstructured":"US Food & Drug Administration.Enhancing the diversity of clinical trial populations\u2014eligibility criteria enrollment practices and trial designs. Accessed December 3 2023.https:\/\/www.fda.gov\/media\/127712\/download"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107243"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)00684\u2010X"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033677"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1012065"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2130"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0887"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.627"},{"key":"e_1_2_11_21_1","unstructured":"ClinicalTrials.gov.Protocol registration data element definitions for interventional and observational studies. Accessed December 3 2023.https:\/\/clinicaltrials.gov\/policy\/protocol-definitions"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911\u2010019\u20100768\u20101"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocy022"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17538157.2020.1828890"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/trgh.2017.0004"},{"key":"e_1_2_11_26_1","unstructured":"ClinicalTrials.gov.Glossary Terms. Accessed December 3 2023.https:\/\/clinicaltrials.gov\/study-basics\/glossary"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.3424"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad009"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117579"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/26895269.2022.2100644"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102017\u2010018121"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2022.100696"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i637"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201023664\u20101"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19517"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000229"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2801"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16038"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/trgh.2019.0053"},{"key":"e_1_2_11_40_1","unstructured":"NCT04216589.Study of Semaglutide for non\u2010alcoholic fatty liver disease (NAFLD) a metabolic syndrome with insulin resistance increased hepatic lipids and increased cardiovascular disease risk (the SLIM LIVER study). Accessed December 3 2023.https:\/\/clinicaltrials.gov\/study\/NCT04216589"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2032447"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfac025"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.02.011"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2234"},{"key":"e_1_2_11_45_1","unstructured":"NCT06001749.Psilocybin in Cancer Pain Study. Accessed December 3 2023.https:\/\/clinicaltrials.gov\/study\/NCT06001749"},{"key":"e_1_2_11_46_1","unstructured":"NCT05719441.A Clinical Trial of Combination HIV\u2010Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission. Accessed December 3 2023.https:\/\/clinicaltrials.gov\/study\/NCT05719441"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25661"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221583"},{"key":"e_1_2_11_49_1","unstructured":"NCT00458393. Emtricitabine\/Tenofovir Disoproxil Fumarate for HIV Prevention in Men (iPrEx). Accessed December 3 2023.https:\/\/clinicaltrials.gov\/study\/NCT00458393"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(15)00206\u20104"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:04:25Z","timestamp":1750305865000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bcp.16076"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16076","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}